IOBTQ — what changed in the latest 10-Q
A section-by-section comparison of IOBTQ's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2025-11-14 vs the prior 10-Q · 2025-08-14
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +29 | −22 | ~25 | 84 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 4 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | Some risk factors updated | +14 | −10 | ~11 | 508 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Other information
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2025-11-14
On August 11, 2025, the Company issued a press release announcing topline results from our Phase 3 trial of Cylembio plus KEYTRUDA® (pembrolizumab) for the treatment of first-line advanced melanoma. In the trial, Cylembio plus pembrolizumab demonstrated clinical improvement in PFS compared to pembro…
The Company is supporting an investigator-initiated study (“IIT”) (NCT05912244) evaluating the combination of Cylembio plus nivolumab-relatlimab for the first-line treatment of patients with unresectable advanced melanoma at three study sites in the United States. The IIT has completed enrollment wi…
On September 29, 2025, the Company issued a press release announcing that the FDA has recommended that the Company not
submit a Biologics License Application (“BLA”) based on the data from the IOB-013 clinical trial. The Company has scheduled a meeting with the FDA in December 2025, to align on the design of a potential new registrational study for Cylembio® in patients with advanced melanoma and plans to discuss th…
As part of the September press release, we also announced that the Company is implementing the Plan to conserve capital while it pursues a pathway to regulatory approval for Cylembio and works to complete ongoing studies. The Company is restructuring to reduce the Company’s ongoing expense structure…
Text removed vs the prior filing · source: 10-Q · 2025-08-14
Our T-win platform is a novel approach to therapeutic cancer vaccines designed to activate pre-existing T cells to target immunosuppressive mechanisms. Our T-win product candidates are designed to employ a dual mechanism of action: (1) direct killing of immune-suppressive cells, including both tumor…
contrast to previous methods that have sought to either block singular immunosuppressive pathways or to direct the immune system against specific identified antigens expressed by tumor cells.
We are developing a pipeline of product candidates that leverage our T-win® platform to address targets within the TME. In addition to melanoma, we are currently evaluating IO102-IO103 in multiple solid tumor indications. We are also focusing on additional targets that play key roles in immunosuppre…
The randomized, open-label study enrolled 407 patients across more than 100 sites worldwide. Patients received either Cylembio® in combination with pembrolizumab (n=203) or pembrolizumab alone (n=204). The primary endpoint was PFS as assessed by a blinded independent review committee per RECIST v1.1…
Improvement in PFS was achieved across virtually all subgroups, regardless of PD-L1 status, including those with poor prognostic factors, with a profound effect in PD-L1 negative patients treated with Cylembio plus pembrolizumab (n=67) compared to patients treated with pembrolizumab monotherapy (n=6…
Risk factors
Text added vs the prior filing · source: 10-Q · 2025-11-14
We have substantial doubt about our ability to continue as a going concern and the Company has been actively seeking, and continues to actively seek, additional capital to fulfill its operating and capital requirements. If additional capital is not available on a timely basis, or at all, the Company…
We have substantial doubt about our ability to continue as a going concern and the Company has been actively seeking, and continues to actively seek, additional capital to fulfill its operating and capital requirements. If additional capital is not available on a timely basis, or at all, the Company…
Since inception, we have devoted substantially all of our efforts to business planning, conducting research and development, recruiting management and technical staff, and raising capital. We have financed our operations primarily through the issuance of convertible preference shares, convertible no…
The Company will require additional capital to develop and obtain regulatory approval for our lead candidate Cylembio®, and to continue to fund future discovery research, preclinical, clinical activities and commercialization of any of our product candidates. If we receive regulatory approval for Cy…
We currently expect that our cash and cash equivalents of $30.7 million as of September 30, 2025, will not be sufficient to fund our operating expenses and capital requirements for at least 12 months from the date the financial statements are issued.
Text removed vs the prior filing · source: 10-Q · 2025-08-14
We have substantial doubt about our ability to continue as a going concern and we will need to obtain substantial additional funding to continue our operations and complete the development and commercialization of our product candidates. If we are unable to raise this capital when needed, we may not…
· We will need to obtain substantial additional funding to complete the development and commercialization of our product candidates. If we are unable to raise this capital when needed, we may be forced to delay, reduce or eliminate our product development programs or other operations.
We have substantial doubt about our ability to continue as a going concern and we will need to obtain substantial additional funding to continue our operations and complete the development and commercialization of our product candidates. If we are unable to raise this capital when needed, we may not…
Since our inception, we have used substantial amounts of cash to fund our operations and expect our expenses to increase substantially during the next few years. The development of biopharmaceutical product candidates, especially immuno-oncology product candidates, is capital intensive. As our produ…
We currently expect that our cash and cash equivalents of $28.1 million as of June 30, 2025, plus €12.5 million in additional funds drawn on July 4, 2025 from the second tranche of the term loan facility with the European Investment Bank (before payment of certain fees and transaction related expens…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice